Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Corporate News: Heidelberg Pharma AG (EQS) +++ HEIDELBERG PHARMA Aktie -5,66%

NFL BIOSCIENCES Aktie

>NFL BIOSCIENCES Performance
1 Woche: -0,8%
1 Monat: +16,7%
3 Monate: -21,7%
6 Monate: -7,7%
1 Jahr: -41,2%
laufendes Jahr: -43,7%
>NFL BIOSCIENCES Aktie
Name:  NFL BIOSCIENCES EO -,03
Land:  Frankreich
Sektor:  Gesundheit
ISIN/ Wkn:  FR0014003XT0 / A3CTQ0
Symbol/ Ticker:  82F (Frankfurt)
Kürzel:  FRA:82F, ETR:82F, 82F:GR
Index:  -
Webseite:  https://www.nflbioscience..
Profil:  NFL Biosciences S.A. is a French biopharmaceutical..
>Volltext..
Marktkapitalisierung:  13.87 Mio. EUR
Unternehmenswert:  10.77 Mio. EUR
Umsatz:  -
EBITDA:  -3.95 Mio. EUR
Nettogewinn:  -3.16 Mio. EUR
Gewinn je Aktie:  -0.28 EUR
Schulden:  0.03 Mio. EUR
Liquide Mittel:  2.94 Mio. EUR
Operativer Cashflow:  -
Bargeldquote:  3.12
Umsatzwachstum:  -
Gewinnwachstum:  -33.25%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  NFL BIOSCIENCES, NFL BIOSCIENCE
Letzte Datenerhebung:  17.12.25
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 12.67 Mio. St.
Frei handelbar: -
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 4
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 131.13%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 7.38
PEG-Ratio: -4.19
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -66.86%
Eigenkaprendite: -153.48%
>Peer Group

Es sind 69 Aktien bekannt.
 
16.10.25 - 17:48
NFL Biosciences Reports Its 2025 Half-Year Results and Provides an Update on Its Development (Business Wire)
 
- Additional studies and analyses confirming the excellent safety profile of NFL-101, its immunological action associated with smoking abstinence, and its rapid and sustained effects on brain regions involved in addiction - Strengthening of the Scientific Advisory Board with world-renowned experts - Financing: €3 million capital increase in May 2025 and €1.2 million in non-dilutive funding obtained in July 2025, extending the cash runway until Q1 2027 - Scientific advice from European agencies and the U.S. FDA expected in the coming daysMONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today announces its half-year results for the period ended June 30, 2025, as approved by the Board of Directors on October 16, 2025, and provides an update on its clinical, industrial and financial developments. Bruno Lafont, Chief Executive Officer a...
22.07.25 - 08:36
NFL Biosciences Secures Initial Non-Dilutive Funding of €1.2 Million, Adding to Its Recent Capital Increase, to Advance the Development of NFL-101, Its First-in-Class Treatment for Tobacco Addiction (Business Wire)
 
A €600,000 “Innovation Advance” repayable advance granted by Bpifrance €600,000 in bank loans granted by Société Générale and Banque Populaire, the company's long-standing banking partners Additional non-dilutive funding expected as well as the Research Tax Credit reimbursement MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL), a biopharmaceutical company developing innovative botanical medicines for the treatment of addiction, today announced that it has secured €1.2 million in medium-term non-dilutive financing from three partners. NFL Biosciences obtained a €600,000 “Innovation Advance” repayable advance from Bpifrance. This advance will be repaid interest-free over 5 years starting in the second quarter of 2029, in quarterly instalments of €30,000. The company has also secured two medium-term loans totalling €600,000 from its banking partners, repayable over 4 and 5 years at a fixed rate. This €1.2 million a...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!